FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:1297-1298 September 22, 2005 Number 12 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Dispenzieri, A. Related Article by Richardson, P. G. PubMed Citation

To the Editor: Richardson et al. (June 16 issue)¹ showed that, in relapsed multiple myeloma, bortezomib improved survival in comparison with high-dose dexamethasone. According to Trippoli et al.² and Sonneveld et al.,³ life expectancy for patients with myeloma who are alive at 1 year after treatment is about 1.5 additional years (range, 0.25³ to 2.47²). Bortezomib costs 49,077 ($59,991 in the United States at the current exchange rates) per patient on the basis of the schedule outlined in the article and current Italian prices.⁴ Considering that some treatment cycles are discontinued early because of side effects or death, the . . . [Full Text of this Article]

This article has been cited by other articles:

• Utecht, K. N., Kolesar, J. (2008). Bortezomib: A novel chemotherapeutic agent for hematologic malignancies. Am J Health Syst Pharm 65: 1221-1231 [Abstract] [Full Text]